US7097832B1 - Intramyocardial injection of autologous bone marrow - Google Patents
Intramyocardial injection of autologous bone marrow Download PDFInfo
- Publication number
- US7097832B1 US7097832B1 US09/868,411 US86841101A US7097832B1 US 7097832 B1 US7097832 B1 US 7097832B1 US 86841101 A US86841101 A US 86841101A US 7097832 B1 US7097832 B1 US 7097832B1
- Authority
- US
- United States
- Prior art keywords
- bone marrow
- autologous bone
- marrow aspirate
- ischemic
- conditioned medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Definitions
- This application is directed to a method of injecting autologous bone marrow. More specifically, this invention is directed to intramyocardial injection of autologous bone marrow to enhance collateral blood vessel formation and tissue perfusion.
- VEGF vascular endoietin-1
- FGF vascular endoietin-1
- angiopoietin-1 vascular endoietin-1
- complex interactions among several growth factor systems are probably necessary for the initiation and maintenance of new blood vessel formation. More specifically, it is believed important to induce a specific localized angiogenic milieu with various angiogenic cytokines interacting in concert and in a time-appropriate manner to initiate and maintain the formation and function of new blood vessels.
- the bone marrow (BM) is a natural source of a broad spectrum of cytokines and cells that are involved in the control of angiogenic processes. It is therefore believed that the intramyocardial injection of autologous (A) BM, by taking advantage of the natural ability of these cells to secrete many angiogenic factors in a time-appropriate manner, provides an optimal intervention for achieving therapeutic collateral development in ischemic myocardium.
- A autologous
- autologous bone marrow is injected, either as a “stand alone” therapeutic agent or combined with any pharmacologic drug, protein or gene or any other compound or intervention that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation, migration, and blood vessel tube formation.
- the “combined” agent(s) can be administered directly into the patient or target tissue, or incubated ex-vivo with bone marrow prior to injection of bone marrow into the patient.
- Non-limiting examples of these “combined” agents are Granulocyte-Monocyte Colony Stimulatory Factor (GM-CSF), Monocyte Chemoattractant Protein 1 (MCP-1), and Hypoxia Inducible Factor-1 (HIF-1).
- An example of an intervention that may enhance bone marrow production of angiogenic factors is ex-vivo exposure of bone marrow cells to hypoxia.
- the autologous bone marrow alone or with “combined” agents, can be delivered to the patient directly via either trans-endocardial or trans-epicardial approaches into either ischemic and/or non-ischemic myocardium, or directly into any other ischemic organ (including a peripheral limb) to enhance and/or promote the development of collateral blood vessel formation and therefore collateral flow to ischemic myocardium or ischemic limbs.
- This approach can also be used to promote the development of newly implanted dedifferentiated and/or differentiated myocardial cells by the process of cardiac myogenesis.
- the invention comprises various autologous bone marrow transplantation strategies to enhance angiogenesis and/or myogenesis and thereby accelerate the development of new blood vessels into ischemic myocardium or lower extremities.
- Another aspect of the invention concerns the strategy of “optimization of angiogenic gene expression.”
- This strategy employs co-administration of HIF-1 with the autologous bone marrow.
- HIF-1 is a transcription factor known to be induced and activated by hypoxia, and known to induce expression of multiple genes involved in the response to hypoxia.
- a similar approach involves the exposure of autologous bone marrow to endothelial PAS domain protein 1 (EPAS1).
- EPAS1 shares high structural and functional homology with HIF-1.
- the strategy also involves the ex-vivo exposure of the bone marrow to hypoxia to increase the production of vascular endothelial growth factor (VEGF) expression or other cytokines with proven angiogene activity (such as MCP-1) prior to its direct injection into the heart or any peripheral ischemic tissue.
- VEGF vascular endothelial growth factor
- MCP-1 proven angiogene activity
- This invention thus includes the direct intramyocardial (trans-epicardial or trans-endocardial) or peripheral intramuscular injection of autologous bone marrow; stimulated autologous bone marrow, for example, stimulated by HIF-1, EPAS1, MCP-1, GM-CSF, or transient exposure to hypoxia or other forms of energy, such as ultrasound, RF, electromagnetic or laser energy; or autologous bone marrow product derived from conditioned medium (acellular component/s of cultured bone marrow).
- the stimulation of the bone marrow could be by the direct exposure of the bone marrow to the factors in the form of proteins, or the bone marrow cells can be transfected with vectors carrying the relevant genes.
- bone marrow can be transfected with a plasmid vector, or with an adenoviral vector, carrying the HIF-1 or EPAS1 transgenes.
- FIG. 1 is a graph of the proliferation of PAEC's vs. the quantities of conditioned medium
- FIG. 2 is a graph of the proliferation of endothelial cells vs. the quantities of conditioned medium
- FIG. 3 is a graph of the concentration of VEGF in conditioned medium over a four-week period of time.
- FIG. 4 is a graph of the concentration of MCP-1 in conditioned medium over a four-week period of time.
- Bone marrow is a natural source of a broad spectrum of cytokines that are involved in the control of angiogenic and inflammatory processes.
- the cytokines expressed comprise mediators known to be involved in the maintenance of early and late hematopoiesis (IL-1 alpha and IL-1 beta, IL-6, IL-7, IL-8, IL-11 and IL-13; colony-stimulating factors, thrombopoietin, erythropoietin, stem cell factor, fit 3-ligand, hepatocyte cell growth factor, tumor necrosis factor alpha, leukemia inhibitory factor, transforming growth factors beta 1 and beta 3; and macrophage inflammatory protein 1 alpha), angiogenic factors (fibroblast growth factors 1 and 2, vascular endothelial growth factor) and mediators whose usual target (and source) is the connective tissue-forming cells (platelet-derived growth factor A, epidermal growth factor, transforming growth factors alpha and beta 2, oncostatin M and insulin-like growth factor
- VEGF polypeptides are present in platelets and megacaryocytes, and are released from activated platelets together with the release of beta-thromboglobulin. Wartiovaara, U., et al., Thromb Haemost 1998; 80:171–5; Mohle, R., Proc Natl Acad Sci USA 1997; 94:663–8.
- angiogenesis is needed to support bone marrow function and development of hematopoietic cells, including stem cells and progenitor cells, that may enter the circulation and target to sites of wound healing and/or ischemia, ultimately contributing to new blood vessel formation.
- Monoclonal antibodies that specifically recognize undifferentiated mesenchymal progenitor cells isolated from adult human bone marrow have been shown to recognize cell surface markers of developing microvasculature, and evidence suggests such cells may play a role in embryonal angiogenesis. Fleming, J. E., Jr., Dev Dyn 1998; 212:119–32.
- Bone marrow angiogensis may become exaggerated in pathologic states where the bone marrow is being activated by malignant cells (such as in multiple myeloma) where bone marrow angiogenesis has been shown to increase simultaneously with progression of human multiple myeloma cells.
- vascular endothelial growth factor (VEGF) has been shown to play a role in the growth of hematopoietic neoplasms such as multiple myeloma, through either a paracrine or an autocrine mechanism. Bellamy, W.
- HIF-1 a potent transcription factor that binds to and stimulates the promoter of several genes involved in responses to hypoxia.
- Induction and activation of HIF-1 is tightly controlled by tissue pO2; HIF-1 expression increases exponentially as pO2 decreases, thereby providing a positive feedback loop by which a decrease in pO2 causes an increase in the expression of gene products that serve as an adaptive response to a low oxygen environment.
- Activation of HIF-1 leads, for example, to the induction of erythropoietin, genes involved in glycolysis, and to the expression of VEGF.
- HIF-1 hypoxia responsive elements
- HIF-1 as determined in HeLa cells
- the inflection point of the curve occurs at an oxygen saturation of 5%, with maximal activity at 0.5% and 1 ⁇ 2 maximal activity at 1.5–2.0%.
- HIF-1 will provide optimal expression of many of the hypoxia-inducible angiogenic genes present in the bone marrow implant.
- the HIF-1 can be injected either as the protein, or as the gene. If as the latter, it can be injected either in a plasmid or viral vector, or any other manner that leads to functionally relevant protein levels.
- bone marrow can be transfected, ex vivo, with a plasmid vector, or with an adenoviral vector, carrying the HIF-1 or EPSA1 transgenes.
- HIF-1 is used in this section as an example of an intervention that could enhance production of angiogenic substances by bone marrow.
- This invention also covers use of other agents, which by enhancing HIF-1 activity (i.e., prolonging its half-life), or by producing effects analgous to HIF-1, stimulate the bone marrow to increase expression of angiogenic factors.
- a similar approach involves the exposure of autologous bone marrow to endothelial PAS domain protein 1 (EPAS1).
- EPAS1 shares high structural and functional homology with HIF-1.
- this invention also includes the ex-vivo exposure of bone marrow cells in culture to hypoxia or other forms of energy, such as, for example, ultrasound, RF, or electromagnetic energy. This intervention increases VEGF and other gene expression. By this effect it may augment the capacity of bone marrow to stimulate angiogenesis.
- Another aspect of the invention involves the ex-vivo stimulation of aspirated autologous bone marrow by HIF-1 (or products that augment the effects of HIF-1 or produce similar effects to HIF-1 on bone marrow) or direct exposure of bone marrow to hypoxic environment followed by the delivery of activated bone marrow cells to the ischemic myocardium or peripheral organ (e.g., ischemic limb) to enhance collateral-dependent perfusion in cardiac and/or peripheral ischemic tissue.
- the stimulation of the bone marrow could be by the direct exposure of the bone marrow to the factors in the form of proteins, or the bone marrow cells can be transfected with vectors carrying the relevant genes.
- bone marrow can be transfected with a plasmid vector, or with an adenoviral vector, carrying the HIF-1 or EPAS1 transgenes.
- monocyte-derived cytokines are activated during collateral growth in vivo, and monocyte chemotactic protein-1 (MCP-1) is upregulated by shear stress in vitro. It has been shown that monocytes adhere to the vascular wall during collateral vessel growth (arteriogenesis) and capillary sprouting (angiogenesis). MCP-1 was also shown to enhance collateral growth after femoral artery occlusion in the rabbit chronic hindlimb ischemia model (Ito et al., Circ Res 1997; 80:829–3). Activation of monocytes seems to play an important role in collateral growth as well as in capillary sprouting. Increased monocyte recruitment by LPS is associated with increased capillary density as well as enhanced collateral and peripheral conductance at 7 days after experimental arterial occlusion (Arras M. et al., J Clin Invest 1998;101:40–50.)
- a further aspect of the invention involves the ex-vivo stimulation of aspirated autologous bone marrow by MCP-1, followed by the direct delivery of activated bone marrow cells to the ischemic myocardium or peripheral organ (e.g., ischemic limb) to enhance collateral-dependent perfusion and muscular function in cardiac and/or peripheral ischemic tissue.
- the stimulation of the bone marrow could be by the direct exposure of the bone marrow to MCP-1 in the form of the protein, or the bone marrow cells can be transfected with a vector carrying the MCP-1 gene.
- bone marrow can be transfected with a plasmid vector, or with an adenoviral vector, carrying the MCP-1 transgene.
- Granulocyte-macrophage colony-stimulating factor GM-CSF
- Granulocyte-Colony Stimulatory Factor G-CSF
- stimulatory cytokines for monocyte maturation and are multipotent hematopoietic growth factors, which are utilized in clinical practice for various hematological pathologies such as depressed white blood cell count (i.e., leukopenia or granulocytopenia or monocytopenia) which occurs usually in response to immunosuppressive or chemotherapy treatment in cancer patients.
- GM-CSF has also been described as a multilineage growth factor that induces in vitro colony formation from erythroid burst-forming units, eosinophil colony-forming units (CSF), and multipotential (CSF), as well as from granulocyte-macrophage CSF and granulocyte CFU.
- CSF erythroid burst-forming units
- CSF eosinophil colony-forming units
- CSF multipotential
- Ex-vivo exposure to GM-CSF has been shown to induce rapid proliferation of CD-34+ progenitor cells (Egeland T. et al., Blood 1991; 78:3192–9.) These cells have the potential to differentiate into vascular endothelial cells and may naturally be involved in postnatal angiogenesis.
- GM-CSF carries multiple stimulatory effects on macrophage/monocyte proliferation, differentiation, motility and survival (reduced apoptotic rate). Consistent with the combined known effects on bone marrow derived endothelial progenitor cells and monocytes, it is another aspect of the invention to use GM-CSF as an adjunctive treatment to autologous bone marrow injections aimed to induce new blood vessel formation and differentiation in ischemic cardiovascular organs.
- GM-CSF may further enhance therapeutic myocardial angiogenesis caused by bone marrow, by augmenting the effect of bone marrow, or by further stimulating, administered either in vivo or in vitro, bone marrow that is also being stimulated by agents such as HIF-1, EPAS1, hypoxia, or MCP-1.
- VEGF vascular endothelial growth factor
- MCP-1 vascular endothelial growth factor-1
- BM cells secreted VEGF and MCP-1, such that their concentrations increased in a time-related manner.
- the resulting conditioned medium enhanced, in a dose-related manner, the proliferation of PAECs.
- the results indicate that BM cells are capable of secreting potent angiogenic cytokines such as VEGF and MCP-1 and of inducing proliferation of vascular endothelial cells.
- Bone marrow (BM) cells were harvested under sterile conditions from pigs with chronic myocardial ischemia in preservative free heparin (20 units/ml BM cells) and filtered sequentially using 300 ⁇ and 200 ⁇ stainless steel mesh filters. BM cells were then isolated by Ficoll-Hypaque gradient centrifugation and cultured in long-term culture medium (LTCM) (Stem Cell Tech, Vancouver, British Columbia, Canada) at 330° C. with 5% CO 2 in T-25 culture flask. The seeding density of the BMCs in each culture was 7 ⁇ 106/ml. Weekly, one half of the medium was removed and replaced with fresh LTCM. The removed medium was filtered (0.2 ⁇ filter) and stored at ⁇ 200° C. for subsequent Enzyme-linked Immunosorbent Assay (ELISA) and cell proliferation assays.
- LTCM long-term culture medium
- ELISA Enzyme-linked Immunosorbent Assay
- Fresh pig aortic endothelial cells were isolated using conventional methods. Endothelial cell growth medium (EGM-2 medium, Clonetics, San Diego, Calif.), containing 2% FBS, hydrocortisone, human FGF, VEGF, human EGF, IGF, heparin and antibiotics, at 37° C. with 5% carbon dioxide. When the cells became confluent at about 7 days, they were split by 2.5% trypsin and cultured thereafter in medium 199 with 10% FBS. Their identity was confirmed by typical endothelial cell morphology and by immunohistochemistry staining for factor VIII. Passage 3–10 were used for the proliferation study.
- PAECs Passage 3–10 were removed from culture flasks by trypsinization. The detached cells were transferred to 96-well culture plates and plated at a seeding density of 5,000 cells/well. Cells were cultured for 2–3 days before being used in proliferation and DNA synthesis experiments. The conditioned medium of BM cells cultures were collected at 4 weeks; medium from 7 culture flasks were pooled and used in the bioassay. Aliquotes (10 ⁇ L, 30 ⁇ L, 100 ⁇ L or 200 ⁇ L) of pooled conditioned medium, or LTCM (200 ⁇ L, as control), were added to confluent PAECs in 96-well plates in triplicate. Four days following culture with conditioned medium or control medium, the PAECs were trypsinized and counted using a cell counter (Coulter Counter Beckman Corporation, Miami Fla.).
- the concentration of VEGF in conditioned medium was measured using a sandwich ELISA kit (Chemicon International Inc., Temecula, Calif.). Briefly, a plate pre-coated with anti-human VEGF antibody was used to bind VEGF in the conditioned medium or to a known concentration of recombinant VEGF. The complex was detected by the biotinylated anti-VEGF antibody, which binds to the captured VEGF. The biotinylated VEGF antibody in turn was detected by streptavidin-alkaline phosphatase and color generating solution. The anti-human VEGF antibody cross-reacts with porcine VEGF.
- the concentration of MCP-1 in conditioned medium was assayed by sandwich enzyme immunoassay kit (R & D Systems, Minneapolis, Minn.): a plate pre-coated with anti human MCP-1 antibody was used to bind MCP-1 in the conditioned medium or to a known concentration of recombinant protein.
- the complex was detected by the biotinylated anti-MCP-1 antibody, which binds to the captured MCP-1.
- the biotinylated MCP-1 antibody in turn was detected by streptavidin-alkaline phosphatase and color generating solution.
- the anti-human MCP-1 antibody cross-reacts with porcine MCP-1.
- the BM conditioned medium collected at four weeks increased, in a dose-related manner, the proliferation of PAECs ( FIG. 1 ). This was demonstrated by counting the number of cells directly and by measuring tritiated thymidine uptake (p ⁇ 0.001 for both measurements). The dose-related response demonstrated a descending limb; proliferation decreased with 200 ⁇ L conditioned medium compared to 30 ⁇ L and 100 ⁇ L (P 0.003 for both comparisons). Similar dose-related results were observed in the tritiated thymidine uptake studies (P 0.03 for 30 ⁇ L and 100 ⁇ L compared to 200 ⁇ L, respectively).
- VEGF and MCP-1 in the BM conditioned medium increased gradually to 10 and 3 times the 1st week level, respectively (P ⁇ 0.001 for both comparisons) ( FIG. 3 ).
- VEGF and MCP-1 levels in a control culture medium, not exposed to BM were 0 and 11 ⁇ 2 pg/ml, respectively, as shown in FIG. 4 .
- hypoxia markedly increases the expression of VEGF by cultured bone marrow endothelial cells, results indicating that ex-vivo exposure to hypoxia, by increasing expression of hypoxia-inducible angiogenic factors, can further increase the collateral enhancing effect of bone marrow cells and its conditioned media to be injected in ischemic muscular tissue.
- Pig bone marrow was harvested and filtered sequentially using 300 ⁇ and 200 ⁇ stainless steel mesh filters. BMCs were then isolated by Ficoll-Hypaque gradient centrifugation and cultured at 33° C. with 5% CO2 in T-75 culture flasks. When cells became confluent at about 7 days, they were split 1:3 by trypsinization.
- the BMCs were either exposed to hypoxic conditions (placed in a chamber containing 1% oxygen) for 24 to 120 hrs, or maintained under normal conditions.
- the resulting conditioned medium was collected and VEGF, MCP-1 were analyzed by ELISA.
- Chronic myocardial ischemia was created in 14 pigs by the implantation of ameroid constrictors around the left circumflex coronary artery.
- 7 animals underwent transendocardial injections of freshly aspirated ABM into the ischemic zone using a transendocardial injection catheter (2.4 ml per animal injected at 12 sites) and 7 control animals were injected with heparinized saline.
- animals Under baseline and 4 weeks later, animals underwent rest and pacing echocardiogram to assess regional contractility (% myocardial thickening), and microsphere study to assess collateral-dependent perfusion at rest and during adenosine infusion.
- BM was aspirated from 2 sites (3 ml per site) using preservative free heparinized glass syringes (20 unit heparin/1 ml fresh BM).
- the aspirated bone marrow was immediately macro-filtered using 300% and 200 ⁇ stainless steel filters, sequentially. Then, the bone marrow was injected using a trans-endocardial injection catheter into the myocardium in 12 sites (0.2 ml per injection site for total of 2.4. ml) directed to the ischemic myocardial territory and its borderline region.
- Transthoracic echocardiography images of short and long axis views at the mid-papillary muscle level were recorded in animals at baseline and during pacing, at baseline and during follow-up evaluation at four weeks after ABM implantation.
- Fractional shortening measurements were obtained by measuring the % wall thickening (end-systolic thickness minus end-diastolic thickness/end-diastolic thickness) ⁇ 100. Those measurements were taken from the ischemic territory (lateral area) and remote territory (anterior-septal area).
- a temporary pacemaker electrode was inserted via a right femoral venous sheath and positioned in the right atrium. Animals were paced at 180/minute for 2 minutes and echocardiographic images were simultaneously recorded.
- Histopathology assessment was performed on sampled heart tissue.
- 7-mm thick short-axis slices were examined under UV light to identify fluorescent-tagged areas. Each identified area was cut into 3 full thickness adjacent blocks (central, right and left) that were immersion-fixed in 10% buffered formaldehyde. Subsequently, each such block was cut into 3 levels, of which 2 were stained with Hematoxylin and Eosin (H&E) and one with PAS.
- H&E Hematoxylin and Eosin
- one fresh fluorescent-labeled tissue block was obtained from the ischemic region of each animal and was embedded in OCT compound (Sakura Finetek USA Inc., Torance, Calif.) and frozen in liquid nitrogen.
- the density of the endothelial population was determined by Sigma-Scan Pro morphometry software using the intensity threshold method.
- the total endothelial area for each sample as well as for each specimen were obtained along with the relative percent endothelial area (endothelial area/area of the myocardium studied).
- the total endothelial area was also calculated as the relative percent of the non-infarcted (viable) area of the myocardium studied.
- the trichrom stained sections were digitized and the area occupied by the blue staining collagen as well as the total area of the section excluding the area occupied by the epicardium (which normally contained collagen) were measured using Sigma-Scan Pro.
- the infarcted area was then calculated as the area occupied by the blue staining.
- the ischemic territory in both groups was characterized by small areas of patchy necrosis occupying overall ⁇ 10% of the examined ischemic myocardium.
- the non-ischemic area revealed normal myocardial structure. Changes in the histomorphometric characteristics of the two groups were compared. There were no differences in the total area occupied by any blood vessel as well as the number of blood vessels >50 ⁇ m in diameter. However, comparison of the total areas stained positive for factor VIII (endothelial cells with and without lumen) in the ischemic versus the non-ischemic territories revealed differences between the 2 groups. In the ABM group, the total endothelial cell area in the ischemic collateral-dependent zone was 100% higher than that observed in the non-ischemic territory (11.6 ⁇ 5.0 vs.
- Chronic myocardial ischemia was created in 16 pigs by the implantation of ameroid constrictors around the left circumflex coronary artery.
- 8 animals underwent subcutaneous injection of GM-CSF for 3 consecutive days (dose 10 ⁇ g/kg per day) followed (on the fourth day and exactly 4 weeks after ameroid implantation) by transendocardial injections of freshly aspirated ABM into the ischemic zone using a transendocardial injection catheter (2.4 ml per animal injected at 12 sites) and 8 control animals without GM-CSF stimulation were injected with heparinized saline.
- Bone marrow ( ⁇ 5 ml) will be aspirated from the iliac crest at approximately 60 minutes prior to initiation of the cardiac procedure using preservative-free heparinized glass syringes (20 unit heparin/1 ml fresh BM).
- the aspirated bone marrow will be immediately macro-filtered using 300 ⁇ and 200 ⁇ stainless steel filters, sequentially. An experienced hematologist will perform the procedure under sterile conditions.
- the bone marrow smear will be evaluated to confirm a normal histomorphology of the bone marrow preparation.
- any of several procedures for delivery of an agent to the myocardium can be used. These include direct transepicardial delivery, as could be achieved by a surgical approach (for example, but not limited to, a transthoracic incision or transthoracic insertion of a needle or other delivery device, or via thoracoscopy), or by any of several percutaneous procedures. Following is one example of percutaneous delivery. It should be emphasized that the following example is not meant to limit the options of delivery to the specific catheter-based platform system described in the example—any catheter-based platform system can be used.
- an introducer sheath of at least 8F is inserted in the right or left femoral artery.
- heparin is administered and supplemented as needed to maintain an ACT for 200–250 seconds throughout the LV mapping and ABM transplantation portion of the procedure.
- ACT will be checked during the procedure at intervals of no longer than 30 minutes, as well as at the end of the procedure to verify conformity with this requirement.
- Left ventriculography is performed in standard RAO and/or LAO views to assist with guidance of NOGA-STARTM and injection catheters, and an LV electromechanical map is obtained using the NOGA-STARTM catheter.
- the 8F INJECTION-STAR catheter is placed in a retrograde fashion via the femoral sheath to the aortic valve. After full tip deflection, the rounded distal tip is gently prolapsed across the aortic valve and straightened appropriately once within the LV cavity.
- the catheter (incorporating an electromagnetic tip sensor) is oriented to one of the treatment zones (e.g. anterior, lateral, inferior-posterior or other).
- the treatment zones e.g. anterior, lateral, inferior-posterior or other.
- needle insertion and injection is allowed only when stability signals will demonstrate an LS value of ⁇ 3.
- a single injection of 0.2 cc of freshly aspirated ABM will be delivered via trans-endocardial approach to the confines of up to two treatment zones with no closer than 5 mm between each injection site.
- the density of injection sites will depend upon the individual subject's LV endomyocardial anatomy and the ability to achieve a stable position on the endocardial surface without catheter displacement or premature ventricular contractions (PVCs).
- autologous bone marrow may be an optimal source for cellular (an example would be endothelial progenitor cells, but the invention is not limited to such cells as many other cells in the bone marrow may contribute importantly to the angiogenic effect) and secreted, e.g., angiogenic growth factors, elements necessary to promote new blood vessel growth and restore function when transferred to another tissue, such as ischemic heart or peripheral limbs.
- a patient's own bone marrow can be used as the key therapeutic source to induce therapeutic angiogensis and/or myogensis in ischemic tissues, e.g., heart muscle and/or ischemic limb, with compromised blood perfusion due to arterial obstructions.
- the patient's own bone marrow is aspirated, i.e., autologous bone marrow donation, processed, and injected directly into ischemia and/or adjacent non-ischemic tissue, e.g., heart muscle and/or ischemic limb, to promote blood vessel growth.
- ischemia and/or adjacent non-ischemic tissue e.g., heart muscle and/or ischemic limb
- the autologous bone marrow and/or bone marrow products are injected into the heart muscle, e.g., the myocardium, by use of either a catheter-based trans-endocardial injection approach or a surgical (open chest or via thoracoscopy) trans-epicardial thoracotomy approach.
- Those two delivery strategies can be used to achieve the same therapeutic goal by promoting the incorporation and integration of angiogenic bone marrow elements in the target organ tissue, e.g., heart muscle and/or ischemic limb.
- autologous bone marrow is administered for treatment.
- the amount administered will depend upon many factors, including, but not limited to, the intended treatment, the severity of a condition being treated, the size and extent of an area to be treated, etc.
- a representative protocol would be to administer quantities of from about 0.2 to about 0.5 ml of autologous bone marrow in each of from about 12 to about 25 injections, for a total of from about 2.4 to about 6 ml of autologous bone marrow being administered.
- Each dose administered could preferably comprise from about 1 to about 2 percent by volume of heparin or another blood anticoagulent, such as coumadin.
- the quantity of autologous bone marrow present should be approximately the same in each dose and/or the total of the autologous bone marrow administered should be about the same as described above. It is believed that the total number of cells of autologous bone marrow administered in each treatment should be on the order of from about 10 7 to 5 ⁇ 10 8 .
- autologous bone marrow transplantation is injected either as a “stand alone” therapeutic agent or combined with any pharmacologic drug, protein or gene or any other compound or intervention that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation, migration, and blood vessel tube formation.
- the “combined” agent(s) can be administered directly into the patient or target tissue, or incubated ex-vivo with bone marrow prior to injection of bone marrow into the patient.
- GM-CSF Granulocyte-Monocyte Colony Stimulatory Factor
- MCP 1 Monocyte Chemoattractant Protein 1
- EPAS1 Hypoxia Inducible Factor-1
- the stimulation of the bone marrow could be by the direct exposure of the bone marrow to the factors in the form of proteins, or the bone marrow cells can be transfected with vectors carrying the relevant genes.
- bone marrow can be transfected with a plasmid vector, or with an adenoviral vector, carrying the HIF-1 or EPAS1 transgenes.
- an intervention that may enhance bone production of angiogenic factors is ex-vivo exposure of bone marrow cells to hypoxia.
- This intervention can be used alone with bone marrow, or in combination with any of the factors outlined above.
- These optimization strategies are designed to increase the production of vascular endothelial growth factor (VEGF) expression and/or other cytokines with angiogene activity prior to the direct injection of the bone marrow into the heart or any peripheral ischemic tissue.
- the invention comprises intramyocardial injection of autologous bone marrow with any agent that would become available to cause stimulation of bone marrow and/or ex-vivo or in vivo stimulation of any angiogenic growth factor production by the bone marrow or its stromal microenvironment.
- patients with refractory coronary artery disease or ischemic peripheral vasculopathy who will be candidates for a bone marrow aspiration procedure followed by autologous bone marrow myocardial or limb transplantation directed into the ischemic tissue or its bordeline zone and/or normal tissue that may serve as the source for collateral or cellular supply to the diseased tissue for the purposes of therapeutic angiogensis and/or myogensis.
- patients with refractory coronary artery disease or ischemic peripheral vasculopathy who will be candidates for a bone marrow aspiration procedure followed by autologous bone marrow myocardial or limb transplantation directed into the ischemic tissue or its bordeline zone and/or normal tissue that may serve as the source for collateral or cellular supply to the diseased tissue for the purposes of therapeutic angiogensis and/or myogensis.
- This procedure will involve the use of a bone marrow aspiration procedure, bone marrow harvesting and processing, followed by the use of the autologous bone marrow or its elements (growth factors and/or cellular elements being isolated from the patient's own bone marrow), with or without any ex-vivo stimulation of its delivery forms, to be injected into the ischemic or non ischemic myocardium and/or peripheral ischemic tissue (such as limb ischemia).
- the bone marrow will be kept in standard anti-coagulation/anti-aggregation solution (containing sodium citrate and EDTA) and kept in 4° C. in sterile medium until the time of its use.
- the bone marrow Upon its use, the bone marrow will be filtered to avoid injecting remaining blood clots or macroaggregates into the target tissue.
- the bone marrow with or without a stimulatory agent in any of its delivery forms, or with or without having been transfected with a vector carrying a transgene that is designed to enhance the angiogenesis effect of the bone marrow, will be injected into the heart muscle, i.e., in therapeutic myocardial angiogenesis or therapeutic myogensis, using either any catheter-based trans-endocardial injection device or via a surgical (open chest) trans-epicardial thoracotomy approach, or any other approach that allows for transepicardial delivery.
- the bone marrow will be transferred by a direct injection of the bone marrow or it elements, with or without ex-vivo or in vivo stimulation in any of its delivery forms, into the muscles of the leg.
- the volume of injection per treatment site will probably range between 0.1–5.0 cc per injection site, dependent upon the specific bone marrow product and severity of the ischemic condition and the site of injection.
- the total number of injections will probably range between 1–50 injection sites per treatment session.
Abstract
Description
TABLE I |
Regional Contractility of the Ischemic Wall |
Baseline | Follow-up | P | ||
Rest | |||||
ABM (%) | 60 ± 32 | 83 ± 21 | 0.04 | ||
Control (%) | 64 ± 46 | 69 ± 48 | 0.74 | ||
Pacing | |||||
ABM (%) | 36 ± 43 | 91 ± 44 | 0.056 | ||
Control (%) | 37 ± 56 | 65 ± 56 | 0.23 | ||
ABM indicates autologous bone marrow. |
TABLE II |
Regional Myocardial Perfusion |
Baseline | Follow-up | P | ||
Rest | |||||
ABM (%) | 83 ± 12 | 98 ± 14 | 0.001 | ||
Control (%) | 89 ± 9 | 92 ± 0.1 | 0.43 | ||
Adenosine | |||||
ABM (%) | 78 ± 12 | 89 ± 18 | 0.025 | ||
Control (%) | 77 ± 5 | 78 ± 11 | 0.75 | ||
ABM indicates autologous bone marrow. |
Claims (15)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/868,411 US7097832B1 (en) | 1999-03-30 | 2000-03-30 | Intramyocardial injection of autologous bone marrow |
US10/618,183 US20040131601A1 (en) | 2000-03-30 | 2003-07-10 | Injection of bone marrow-derived cells and medium for angiogenesis |
US10/776,545 US20040161421A1 (en) | 1999-03-30 | 2004-02-10 | Intramyocardial injection of autologous bone marrow |
US11/117,607 US20060051334A1 (en) | 1999-03-30 | 2005-04-27 | Injection of bone marrow-derived conditioned medium for angiogenesis |
US11/221,469 US20060057722A1 (en) | 1999-03-30 | 2005-09-07 | Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12680099P | 1999-03-30 | 1999-03-30 | |
US13837999P | 1999-06-09 | 1999-06-09 | |
US09/868,411 US7097832B1 (en) | 1999-03-30 | 2000-03-30 | Intramyocardial injection of autologous bone marrow |
PCT/US2000/008353 WO2000057922A1 (en) | 1999-03-30 | 2000-03-30 | Intramyocardial injection of autologous bone marrow |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/008353 A-371-Of-International WO2000057922A1 (en) | 1999-03-30 | 2000-03-30 | Intramyocardial injection of autologous bone marrow |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16051402A Continuation-In-Part | 1999-03-30 | 2002-05-30 | |
US10/776,545 Division US20040161421A1 (en) | 1999-03-30 | 2004-02-10 | Intramyocardial injection of autologous bone marrow |
Publications (1)
Publication Number | Publication Date |
---|---|
US7097832B1 true US7097832B1 (en) | 2006-08-29 |
Family
ID=32854188
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/868,411 Expired - Lifetime US7097832B1 (en) | 1999-03-30 | 2000-03-30 | Intramyocardial injection of autologous bone marrow |
US10/776,545 Abandoned US20040161421A1 (en) | 1999-03-30 | 2004-02-10 | Intramyocardial injection of autologous bone marrow |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/776,545 Abandoned US20040161421A1 (en) | 1999-03-30 | 2004-02-10 | Intramyocardial injection of autologous bone marrow |
Country Status (1)
Country | Link |
---|---|
US (2) | US7097832B1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020172663A1 (en) * | 2001-01-23 | 2002-11-21 | Maria Palasis | Localized myocardial injection method for treating ischemic myocardium |
US20020192198A1 (en) * | 1998-04-21 | 2002-12-19 | Elia James P. | Method for growing human organs and suborgans |
US20040180043A1 (en) * | 2001-09-19 | 2004-09-16 | Hani Sabbah | Cardiac transplantation of stem cells for the treatment of heart failure |
US20050147597A1 (en) * | 2000-07-26 | 2005-07-07 | Takafumi Ueno | Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue |
US20060089309A1 (en) * | 2004-10-07 | 2006-04-27 | Stem Cell Therapeutics Corp. | Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
US20060211955A1 (en) * | 2000-08-24 | 2006-09-21 | Horzewski Michael J | Systems and methods for applying ultrasound energy to stimulating circulatory activity in a targeted body region of an individual |
US20070071735A1 (en) * | 1993-04-27 | 2007-03-29 | Elia James P | Method and apparatus for installation of dental implant |
US20090143748A1 (en) * | 2007-08-09 | 2009-06-04 | Boston Scientific Scimed, Inc | Catheter Devices for Myocardial Injections or Other Uses |
US20090169527A1 (en) * | 2002-01-14 | 2009-07-02 | Henry Ford Health System | Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors |
US20090299269A1 (en) * | 2008-05-29 | 2009-12-03 | John Foley | Vascular stimulation to aid intravascular cell replacement therapy |
US20100209398A1 (en) * | 2009-02-04 | 2010-08-19 | Nikolai Tankovich | Compositions of stem cells and stem cell factors and methods for their use and manufacture |
US7871605B2 (en) | 2006-11-03 | 2011-01-18 | Aastrom Bioscience, Inc. | Mixed cell populations for tissue repair and separation technique for cell processing |
WO2011041478A1 (en) | 2009-10-02 | 2011-04-07 | Baxter International Inc. | Hematopoietic stem cells for use in the treatment of a kidney injury |
US20110165131A1 (en) * | 1994-06-30 | 2011-07-07 | Elia James P | Methods for treating diseases and increasing longevity |
WO2013126590A2 (en) | 2012-02-21 | 2013-08-29 | Baxter International Inc. | Pharmaceutical composition comprising cd34+ cells |
WO2015066076A1 (en) | 2013-10-28 | 2015-05-07 | Biocardia, Inc. | Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291597B2 (en) | 2000-04-06 | 2007-11-06 | Franco Wayne P | Growth factor therapy mobilization of stem cells into the peripheral blood |
US7840263B2 (en) | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US8060219B2 (en) | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
US7736346B2 (en) | 2005-10-18 | 2010-06-15 | Biocardia, Inc. | Bio-interventional therapeutic treatments for cardiovascular diseases |
US8496926B2 (en) | 2007-04-16 | 2013-07-30 | Biocardia, Inc. | Treatment for chronic myocardial infarction |
AU2015274367B2 (en) | 2014-06-13 | 2020-11-26 | Beth Israel Deaconess Medical Center, Inc. | Products and methods to isolate mitochondria |
WO2017095940A1 (en) | 2015-11-30 | 2017-06-08 | Flagship Pioneering, Inc. | Methods and compositions relating to chondrisomes from cultured cells |
JP7185527B2 (en) * | 2016-01-15 | 2022-12-07 | ザ チルドレンズ メディカル センター コーポレーション | Therapeutic use of mitochondria and combined mitochondrial agents |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004274A1 (en) | 1989-09-25 | 1991-04-04 | Genetics Institute, Inc. | Method for inhibiting growth of stem cells |
US5610056A (en) * | 1994-11-16 | 1997-03-11 | Amgen Inc. | Use of stem cell factor interleukin-6 and soluble interleukin-6 receptor to induce the development of hematopoietic stem cells |
US5817773A (en) | 1990-06-08 | 1998-10-06 | New York University | Stimulation, production, culturing and transplantation of stem cells by fibroblast growth factors |
WO1999000486A1 (en) | 1997-06-26 | 1999-01-07 | Cli Oncology, Inc. | Compositions and methods for inducing the development and differentiation of hemopoietic stem cells |
US5980893A (en) * | 1997-07-17 | 1999-11-09 | Beth Israel Deaconess Medical Center, Inc. | Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis |
US5997860A (en) * | 1992-11-24 | 1999-12-07 | G. D. Searle & Co. | Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines |
US6013780A (en) | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
WO2000057922A1 (en) | 1999-03-30 | 2000-10-05 | Ran Kornowski | Intramyocardial injection of autologous bone marrow |
US6676937B1 (en) * | 1998-03-09 | 2004-01-13 | Caritas St. Elizabeth's Medical Center Of Boston Inc. | Compositions and methods for modulating vascularization |
US20050031600A1 (en) * | 1998-07-31 | 2005-02-10 | Genzyme Corporation | Cardiac function by mesenchymal stem cell transplantation |
-
2000
- 2000-03-30 US US09/868,411 patent/US7097832B1/en not_active Expired - Lifetime
-
2004
- 2004-02-10 US US10/776,545 patent/US20040161421A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004274A1 (en) | 1989-09-25 | 1991-04-04 | Genetics Institute, Inc. | Method for inhibiting growth of stem cells |
US5817773A (en) | 1990-06-08 | 1998-10-06 | New York University | Stimulation, production, culturing and transplantation of stem cells by fibroblast growth factors |
US5997860A (en) * | 1992-11-24 | 1999-12-07 | G. D. Searle & Co. | Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines |
US5610056A (en) * | 1994-11-16 | 1997-03-11 | Amgen Inc. | Use of stem cell factor interleukin-6 and soluble interleukin-6 receptor to induce the development of hematopoietic stem cells |
US6013780A (en) | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
WO1999000486A1 (en) | 1997-06-26 | 1999-01-07 | Cli Oncology, Inc. | Compositions and methods for inducing the development and differentiation of hemopoietic stem cells |
US5980893A (en) * | 1997-07-17 | 1999-11-09 | Beth Israel Deaconess Medical Center, Inc. | Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis |
US6676937B1 (en) * | 1998-03-09 | 2004-01-13 | Caritas St. Elizabeth's Medical Center Of Boston Inc. | Compositions and methods for modulating vascularization |
US20050031600A1 (en) * | 1998-07-31 | 2005-02-10 | Genzyme Corporation | Cardiac function by mesenchymal stem cell transplantation |
WO2000057922A1 (en) | 1999-03-30 | 2000-10-05 | Ran Kornowski | Intramyocardial injection of autologous bone marrow |
Non-Patent Citations (37)
Title |
---|
Anderson, "Human gene therapy", Nature, 392(6679 Supp.):25-30 (Apr. 1998). |
Aoki et al. Blood. Jun. 1999; 93:4034-43. * |
Asahara, T. et al., "Gene therapy of endothelial progenitor cell for vascular development in severe ischemic disease", Circulation, vol. 100, (1999) pp. 1-481, Abstract XP009051610. |
B.E. Strauer, M.D., et al., "Stem Cell Therapy in Perspective," Circulation, 2003, vol. 107, pp. 929-934. |
Bickenbach et al., "Selection and Extended Growth of Murine Epidermal Stem Cells in Culture", Exp. Cell Res., 244(1):184-195 (Oct. 1998). |
Blanquaert et al., "RGTA modulates the healing pattern of a defect in a monolayer of osteoblastic cells by acting on both proliferation and migration", J. Biomed. Mater. Res., 64A(3):525-532 (Mar. 2003). |
Blume and Thomas, "A Review of Autologous Hematopoietic Cell Transplantation," Biology of Blood and Marrow Transplantation, vol. 6, 2000, pp. 1-12. |
Brugger, Wolfram et al., "Ex Vivo Manipulation of Hematopoietic Stem and Progenitor Cells," Seminars in Hematology, vol. 37, No. 1, Supplement 2, Jan. 2000, pp. 42-49. |
C. Kalka, et al., "Angiogenesis and Vasculogenesis," Herz, 2000, vol. 25, No. 6, pp. 611-622. |
Cashman et al. Blood, 1998; 92: 2338-44. * |
Chiu, "Adult stem cell therapy for heart failure", Expert Opin Biol Ther., Apr. 2003, 3(2):215-25. |
Chiu, RC. Expert. Opin. Biol. Ther. 2003; 3(2):215-25. * |
Desgranges et al., "Beneficial use of fibroblast growth factor 2 and RGTA, a new family of heparan mimics, for endothelialization of PET prostheses", J Biomed Mater Res., 2001, 58(1):1-9. |
Dini, G. et al., "Peripheral Blood Stem Cell Collection from G-CSF-Stimulated Unrelated Donors for Second Transplant," Bone Marrow Transplantation, vol. 22, Supplement 5, 1998, pp. S41-S45. |
Dowell et al., "Myocyte and myogenic stem cell transplantation in the heart", Cardiovasc Res., May 2003, 58(2):336-50. |
Dubrey et al., "Improvement of Echocardiographic and Electrocardiographic features in AL Cardiac Amyloidosis with Intensive Melphalan and Autologous Stem Cell Rescue" Boston University School of Medicine, XP-00107 135. |
Fielding and Goldstone, "Autologous Bone Marrow Transplantation," Current Opinion in Hematology, vol. 1, 1994, pp. 412-417. |
Folkman, "Therapeutic angiogenesis in ischemic limbs", Circulation, Mar. 1998, 97(12):1108-10. |
Fuchs et al. J. Am. Coll. Cardiol. 2001; 37: 1726-32. * |
Isner and Asahara, "Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization" The Journal of Clinical Investigation 103 (9):1231-1236 (1999). |
Isner, Jeffrey M., "Myocardial gene Theapy", Nature (London) vol. 415, No. 6868, (2002) pp. 234-239. |
Iwaguro et al., "Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration", Circulation,, Feb. 2002, 105(6):732-8. |
Kanj, Souha S. et al., "Myocardial Ischemia Associated With High-Dose Carmustine Infusion," Cancer, vol. 68, Nov. 1, 1991, pp. 1910-1912. |
Karen K. Fields, "Autologous Bone Marrow Transplantation and Melanoma: A Focused Review of the Literature" Annals of Plastic Surgery 28 (1):70-73 (1992), XP-001069809. |
Liechty et al. Nat. Med. 2000; 6(11): 1282-1286. * |
Mack et al. J. Thor. Cardio. Surg. 1998; 115:168-77. * |
Noishiki et al., "Autocrine angiogenic vascular prosthesis with bone marrow transplantation" Nature Medicine, 2 (1):90-93 (1996). |
Noishiki, Yasuharu et al., "Angiogenic Growth Factor Release System for In Vivo Tissue Engineering: A Trial of Bone Marrow Transplantation into Ischemic Myocardium," J. Artif. Organs, vol. 2, 1999, pp. 85-91. |
Perin et al. Circulation, 2003; 107 :2294-2302. * |
S. Fuchs, et al., "Transendocardial Delivery of Autologous Bone Marrow Enhances Collateral Perfusion and Regional Function in Pigs with Chronic Experimental Myocardial Ischemia," Journal of American College of Cardiology, 2001, vol. 37, No. 6, pp. 1726-1732. |
Simnett, S.J. et al., "Autologous Stem Cell Transplantation for Malignancy: A Systematic Review of the Literature," Clin. Lab. Haem., vol. 22, 2000, pp. 61-72. |
Stamm et al. Lancet, 2003 ; 361 :45-6. * |
Tao and Ma. Pathology, 2003; 35:6-13. * |
Tomita et al. Circulation, 1999 ; 100(Supp II) :II-247-II-256. * |
Tomita et al., "Autotransplanted Mesenchymal Stem Cells Improve Functions After A Myocardial Infarction," Circulation 98 (17):1200 Abstract 1037. |
Vaughan, William P., et al., "Roundtable Discussion: Incorporating Bone Marow Transplantation Into NCCN Guidelines," Onocology, vol. 12, No. 11A, NCCN Proceedings, Nov. 1998, pp. 390-392. |
Yamauchi et al., "New agents for the treatment of infracted myocardium" The FASEB Journal 10.1096/fj.99-0565fje (2000). |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080095709A1 (en) * | 1993-04-27 | 2008-04-24 | Ella James P | Method and apparatus for installation of dental implant |
US20080019951A1 (en) * | 1993-04-27 | 2008-01-24 | Elia James P | Method and apparatus for installation of dental implant |
US9566135B2 (en) * | 1993-04-27 | 2017-02-14 | DENTAL MARKETING SPECIALISTS, INC., an Arizona Corp | Method of growing an artery |
US20070071736A1 (en) * | 1993-04-27 | 2007-03-29 | Elia James P | Method and apparatus for installation of dental implant |
US20070071735A1 (en) * | 1993-04-27 | 2007-03-29 | Elia James P | Method and apparatus for installation of dental implant |
US20110165131A1 (en) * | 1994-06-30 | 2011-07-07 | Elia James P | Methods for treating diseases and increasing longevity |
US20020192198A1 (en) * | 1998-04-21 | 2002-12-19 | Elia James P. | Method for growing human organs and suborgans |
US7799349B2 (en) * | 2000-07-26 | 2010-09-21 | Boston Scientific Scimed, Inc. | Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue |
US20050147597A1 (en) * | 2000-07-26 | 2005-07-07 | Takafumi Ueno | Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue |
US20060211955A1 (en) * | 2000-08-24 | 2006-09-21 | Horzewski Michael J | Systems and methods for applying ultrasound energy to stimulating circulatory activity in a targeted body region of an individual |
US20080254109A1 (en) * | 2001-01-23 | 2008-10-16 | Maria Palasis | Localized myocardial injection method for treating ischemic myocardium |
US20020172663A1 (en) * | 2001-01-23 | 2002-11-21 | Maria Palasis | Localized myocardial injection method for treating ischemic myocardium |
US7658951B2 (en) * | 2001-09-19 | 2010-02-09 | Henry Ford Health System | Method of improving cardiac function of a diseased heart |
US20040180043A1 (en) * | 2001-09-19 | 2004-09-16 | Hani Sabbah | Cardiac transplantation of stem cells for the treatment of heart failure |
US20090169527A1 (en) * | 2002-01-14 | 2009-07-02 | Henry Ford Health System | Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors |
US7994131B2 (en) * | 2004-10-07 | 2011-08-09 | Stem Cell Therapeutics Corp. | Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
US20060089309A1 (en) * | 2004-10-07 | 2006-04-27 | Stem Cell Therapeutics Corp. | Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
US20110076294A1 (en) * | 2006-11-03 | 2011-03-31 | Aastrom Biosciences, Inc. | Mixed Cell Populations For Tissue Repair And Separation Technique For Cell Processing |
US9415071B2 (en) | 2006-11-03 | 2016-08-16 | Vericel Corporation | Mixed cell populations for tissue repair and separation technique for cell processing |
US7871605B2 (en) | 2006-11-03 | 2011-01-18 | Aastrom Bioscience, Inc. | Mixed cell populations for tissue repair and separation technique for cell processing |
US8394631B2 (en) | 2006-11-03 | 2013-03-12 | Aastrom Biosciences, Inc. | Mixed cell populations for tissue repair and separation technique for cell processing |
US20110124105A1 (en) * | 2006-11-03 | 2011-05-26 | Aastrom Biosciences, Inc. | Mixed Cell Populations For Tissue Repair And Separation Technique For Cell Processing |
US8158122B2 (en) | 2006-11-03 | 2012-04-17 | Aastrom Biosciences Inc. | Mixed cell populations for tissue repair and separation technique for cell processing |
US20090143748A1 (en) * | 2007-08-09 | 2009-06-04 | Boston Scientific Scimed, Inc | Catheter Devices for Myocardial Injections or Other Uses |
US8292873B2 (en) | 2007-08-09 | 2012-10-23 | Boston Scientific Scimed, Inc. | Catheter devices for myocardial injections or other uses |
US20090299269A1 (en) * | 2008-05-29 | 2009-12-03 | John Foley | Vascular stimulation to aid intravascular cell replacement therapy |
US20100209398A1 (en) * | 2009-02-04 | 2010-08-19 | Nikolai Tankovich | Compositions of stem cells and stem cell factors and methods for their use and manufacture |
US8790638B2 (en) | 2009-02-04 | 2014-07-29 | Stemedica Cell Technologies, Inc. | Compositions of stem cells and stem cell factors and methods for their use and manufacture |
US20110091427A1 (en) * | 2009-10-02 | 2011-04-21 | Baxter International Inc. | Methods for treating a kidney injury |
WO2011041478A1 (en) | 2009-10-02 | 2011-04-07 | Baxter International Inc. | Hematopoietic stem cells for use in the treatment of a kidney injury |
WO2013126590A2 (en) | 2012-02-21 | 2013-08-29 | Baxter International Inc. | Pharmaceutical composition comprising cd34+ cells |
WO2015066076A1 (en) | 2013-10-28 | 2015-05-07 | Biocardia, Inc. | Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies |
US9945854B2 (en) | 2013-10-28 | 2018-04-17 | Biocardia Inc. | Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies |
US10520505B2 (en) | 2013-10-28 | 2019-12-31 | Biocardia, Inc. | Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies |
EP3593810A1 (en) | 2013-10-28 | 2020-01-15 | Biocardia, Inc. | Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies |
US11828757B2 (en) | 2013-10-28 | 2023-11-28 | Biocardia, Inc. | Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies |
Also Published As
Publication number | Publication date |
---|---|
US20040161421A1 (en) | 2004-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7097832B1 (en) | Intramyocardial injection of autologous bone marrow | |
CA2368677C (en) | Intramyocardial injection of autologous bone marrow | |
US20040131601A1 (en) | Injection of bone marrow-derived cells and medium for angiogenesis | |
CA2504019C (en) | Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy | |
US20040161412A1 (en) | Cell-based VEGF delivery | |
US20030232050A1 (en) | Compositions and methods for regulating angiogenesis | |
WO1993013807A1 (en) | A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy | |
WO2005104766A2 (en) | Injection of bone marrow-derived conditioned medium for angiogenesis | |
US20060057722A1 (en) | Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment | |
US20060051334A1 (en) | Injection of bone marrow-derived conditioned medium for angiogenesis | |
CA2487410C (en) | Intramyocardial injection of autologous bone marrow | |
US20070173471A1 (en) | Morphogen compositions and methods of use thereof to treat heart disorders | |
AU2005282384B2 (en) | Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment | |
WO2005028616A2 (en) | Morphogen compositions and methods of use thereof to treat heart disorders | |
KR20060107745A (en) | Fibroblast-mobilizing agent containing g-csf and wound remedy | |
KR20150009655A (en) | Compositions comprising adipose-derived mesenchymal stem cell overexpressing gcp-2 gene for treating ischemic disease | |
US20190382728A1 (en) | Menstrual Blood Derived Angiogenesis Stimulatory Cells | |
AU2010241483B2 (en) | Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration | |
CN117919400A (en) | IPS induced directional differentiation endothelial progenitor cell and antibody combined treatment of cardiovascular and cerebrovascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MYOCARDIAL THERAPEUTICS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KORNOWSKI, RAN;FUCHS, SHMUEL;EPSTEIN, STEPHEN E.;AND OTHERS;REEL/FRAME:017853/0700 Effective date: 20060627 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: MEDIVAS, LLC, CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SATOMI, HAJIME;REEL/FRAME:025550/0874 Effective date: 20101109 Owner name: BIOMET BIOLOGICS, LLC, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDIVAS, LLC;REEL/FRAME:025505/0487 Effective date: 20101123 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553) Year of fee payment: 12 |
|
AS | Assignment |
Owner name: BIOMET, INC., INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOMET BIOLOGICS, LLC;REEL/FRAME:045914/0262 Effective date: 20171103 Owner name: BIOMET MANUFACTURING, LLC, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZB MANUFACTURING, LLC;REEL/FRAME:045914/0335 Effective date: 20171103 Owner name: ZB MANUFACTURING, LLC, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOMET, INC.;REEL/FRAME:045914/0350 Effective date: 20171103 |